These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1495559)

  • 1. Coley's vaccine and TNF therapy.
    Brouckaert PG; Fiers W; Lejeune FJ
    Nature; 1992 Aug; 358(6388):630. PubMed ID: 1495559
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumours and Coley's toxins.
    Rook G
    Nature; 1992 Jun; 357(6379):545. PubMed ID: 1608465
    [No Abstract]   [Full Text] [Related]  

  • 3. Coley's toxins and chemotherapy in treatment of breast carcinosarcoma: case report.
    Chandler JJ; Crisera RV; Fletcher WS
    Am Surg; 1969 May; 35(5):377-83. PubMed ID: 5782243
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumour necrosis factor and cancer treatment: a historical review and perspectives.
    Terlikowski SJ
    Rocz Akad Med Bialymst; 2001; 46():5-18. PubMed ID: 11780579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor, cancer and anticancer therapy.
    Mocellin S; Rossi CR; Pilati P; Nitti D
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):35-53. PubMed ID: 15733831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient increase of plasma interleukin-6 after infusion of recombinant tumor necrosis factor alpha in advanced cancer patients.
    Zubelewicz B; Romanowski W; Braczkowska B; Lissoni P; Braczkowski R
    J Exp Clin Cancer Res; 1998 Dec; 17(4):449-52. PubMed ID: 10089067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coley's toxins in perspective.
    Starnes CO
    Nature; 1992 May; 357(6373):11-2. PubMed ID: 1574121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from Coley's Toxin.
    Tsung K; Norton JA
    Surg Oncol; 2006 Jul; 15(1):25-8. PubMed ID: 16814541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.
    Wiemann B; Starnes CO
    Pharmacol Ther; 1994; 64(3):529-64. PubMed ID: 7724661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous and exogenous TNF therapy (EET therapy): conceptual and experimental grounds.
    Mizuno D; Soma GI
    Ann Inst Pasteur Immunol; 1988; 139(3):282-5. PubMed ID: 3048309
    [No Abstract]   [Full Text] [Related]  

  • 11. Coley's toxins.
    Starnes CO
    Nature; 1992 Nov; 360(6399):23. PubMed ID: 1436069
    [No Abstract]   [Full Text] [Related]  

  • 12. Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.
    Eggermont AM; Manusama ER; ten Hagen TL
    J Inflamm; 1995-1996; 47(1-2):104-13. PubMed ID: 8913937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor necrosis factor-alpha--biological and immunologic properties].
    Chciałowski A; Targowski T; Bajera I; Jahnz-Rózyk K
    Pol Merkur Lekarski; 1997 Jun; 2(12):392-5. PubMed ID: 9424334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.
    Gerspach J; Pfizenmaier K; Wajant H
    Biofactors; 2009; 35(4):364-72. PubMed ID: 19484741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications.
    de Vries EG; Gietema JA; de Jong S
    Clin Cancer Res; 2006 Apr; 12(8):2390-3. PubMed ID: 16638843
    [No Abstract]   [Full Text] [Related]  

  • 18. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).
    McLaughlin PJ; Elwood NJ; Russell SM; Andrew SM; McKenzie IF
    Anticancer Res; 1992; 12(4):1243-6. PubMed ID: 1503416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
    Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
    Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
    McLoughlin JM; McCarty TM; Cunningham C; Clark V; Senzer N; Nemunaitis J; Kuhn JA
    Ann Surg Oncol; 2005 Oct; 12(10):825-30. PubMed ID: 16132372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.